Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Olanzapine Augmentation Therapy in Treatment-Resistant Depression: a Double-Blind Placebo-Controlled Trial

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University Hospital Freiburg.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital Freiburg
ClinicalTrials.gov Identifier:
NCT00273624
First received: January 4, 2006
Last updated: February 17, 2009
Last verified: February 2009

January 4, 2006
February 17, 2009
June 2005
December 2009   (final data collection date for primary outcome measure)
Hamilton-Depression-Scale- HAM-D [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Hamilton-Depression-Scale- HAM-D
Complete list of historical versions of study NCT00273624 on ClinicalTrials.gov Archive Site
  • rate of remission (HAM-D less or equal 7) [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  • differences in HAM-D total scores [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  • differences in MADRS (Montgomery Asberg Depression Rating Scale)and CGI (Clinical Global Impression)scores [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  • predictive value of HAM-D subscales for treatment response use of comedication [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  • survival in study [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
  • differences in rates of adverse events, weight [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
  • differences in HAM-D scores and survival in extension phase [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]
  • -rate of remission (HAM-D less or equal 7)
  • -differences in HAM-D total scores
  • -differences in MADRS (Montgomery Asberg Depression Rating Scale)and CGI (Clinical Global Impression)scores
  • -predictive value of HAM-D subscales for treatment response
  • -use of comedication
  • -survival in study
  • -differences in rates of adverse events, weight
  • -differences in HAM-D scores and survival in extension phase
Not Provided
Not Provided
 
Olanzapine Augmentation Therapy in Treatment-Resistant Depression: a Double-Blind Placebo-Controlled Trial
Olanzapine Augmentation Therapy in Treatment-Resistant Depression: a Double-Blind Placebo-Controlled Trial

60 patients with major depression will be treated with 10 mg Olanzapine or Placebo for 2 weeks. In case of response (reduction of depressive symptoms)the study will be continued for further 60 days.

The study is using a randomized double-blind, parallel-group, placebo-controlled design. 30 patients per treatment group will be included into the study and randomized to the treatment groups using a computer program. Psychotic features of depression will be excluded by a score of 2 or less in the PANSS subscales P1, P3 and P6. Treatment resistance as defined by history of non-response to two antidepressants from different classes at an acceptable dose and period is confirmed retrospectively. If possible, treatment compliance should be confirmed by plasma level examination. After informed consent, visit 1 is performed on day 0 (inclusion criteria, history, demographics, physical examination, vital signs, HAMD, MADRS, CGI, lab). Study medication is started on day 1, the antidepressive therapy is continued at stable dose until the end of the study. Patients will receive a double-blind therapy of either 10 mg/d olanzapine or placebo. Study visits will be performed on days 4, 7, and 14 (visits 2-4: vital signs, HAMD, MADRS, CGI, lab).

After 14 days, the patients will be classified as responders or non-responders. A responder is defined by a reduction of the initial HAM-D score of more than 50%. Study treatment will be stopped in non-responders and continued in a double-blind manner in responders for further 60 days. Thereafter, the the study medication is stopped and the patients are observed for further 14 days. Study visits will be performed every 14 days. This extension phase was added to examine if a prolonged treatment with olanzapine could ensure a sustained treatment effect. It should be excluded that olanzapine has a short-term tranquillizer-like effect or leads to unfavourable medium- to-long-term depressiogenic effects as observed with other neuroleptics used in depression ( e.g. fluspirilene). Moreover, withdrawal effects should be excluded.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Therapy-Resistant Depression
  • Drug: Olanzapine
    10 mg Olanzapin concurrent to antidepressive medication
    Other Name: Zyprexa
  • Drug: Placebo
    placebo
  • Experimental: olanzapine
    10 mg Olanzapine
    Intervention: Drug: Olanzapine
  • Placebo Comparator: placebo
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • major depression without psychotic features
  • therapy resistance (2 courses of antidepressants from different classes for more than 3 weeks in adequate dose
  • HAM-D score greater/equal than 17
  • age 18-65

Exclusion Criteria:

  • bipolar disorder
  • active alcohol or illicit drug use
  • female with ineffective contraception
  • severe medical conditions, epilepsy
  • psychotic features
Both
18 Years to 65 Years
No
Contact: Claus Normann, MD ++497612706634 claus.normann@uniklinik-freiburg.de
Germany
 
NCT00273624
Olanzapine Augmentation
No
Dr. Claus Normann, Dept. Of Psychiatry University of Freiburg
University Hospital Freiburg
Not Provided
Principal Investigator: Claus Normann, MD Department of Psychiatry, University of Freiburg
University Hospital Freiburg
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP